Precision Medicine in Prostate Cancer VL

The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris

Details
Alicia Morgans, MD, MPH, is joined by Michael Morris, MD, to discuss the phase III VISION trial results and the practice-changing implications when lutetium-177-PSMA-617 is FDA approved. The VISION trial evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined standard of care with...

PSMA Molecular Targeted Radiation Therapy - Andrei H. Iagaru

Details
Detection and Localization of Prostate Cancer: Case-based Scan Reading Review PSMA Molecular Targeted Radiation Therapy - Part Three of Three- Scan Reader Training and Discussions Presenter: Andrei Iagaru. Independent Medical Education Initiative Supported by Novartis Pharmaceutical Corporation Biographies: Program Presenter: Andrei H. Iagaru, MD, FACNM, Professor of Radiology - Nuclear Medicine,...

Demonstrating PSMA Molecular Diagnostic Imaging with18F-DCFPyL or 68Ga-PSMA11 for Prostate Cancer Staging and Clinical Case Discussions - Andrei H. Iagaru

Details
Detection and Localization of Prostate Cancer: Case-based Scan Reading Review Demonstrating PSMA Molecular Diagnostic Imaging with18F-DCFPyL or 68Ga-PSMA11 for Prostate Cancer Staging and Clinical Case Discussions - Part Two of Three in Scan Reader Training and Discussions. Independent Medical Education Initiative Supported by Novartis Pharmaceutical Company Biographies: Program Presenter: Andrei...

18F-Fluciclovine in Biochemical Recurrent Prostate Cancer - Andrei H. Iagaru

Details
Detection and Localization of Prostate Cancer: Case-based Scan Reading Review 18F-Fluciclovine Cases - Part One of Three - Scan Reader Training and Discussions Presenter: Andrei Iagaru. Independent Medical Education Initiative Supported by Advanced Accelerator Applications, A Novartis Company Biographies: Program Presenter: Andrei H. Iagaru, MD, FACNM, Professor of Radiology - Nuclear Medicine, Ch...

DNA Repair and PARP Inhibitor Therapy in Prostate Cancer - Veda Giri, Patrick Pilié, and Arpit Rao

Details
Charles Ryan, MD, is joined by Veda Giri, MD, Patrick Pilié, MD, and Arpit Rao, MD, MBBS, for a roundtable discussion on DNA repair and Poly (ADP-ribose) polymerase (PARP) inhibitor therapy in prostate cancer. To begin, Dr. Giri discusses the need for widespread genetic testing in the clinic today. Following the May 2020 United States Federal Drug Administration (FDA) approvals of PARP inhibitors...

Integrating Genetics and Genomics into Treatment Decisions for Men with Prostate Cancer - Panagiotis Vlachostergios

Details
Panagiotis Vlachostergios, MD, PhD, joins Alicia Morgans, MD, MPH, to discuss germline and somatic genetic testing and the ways in which genomic material can be integrated into clinical practice. Dr. Morgans and Dr. Vlachostergios agree that patients with metastatic disease, among others, should undergo germline genetic testing, and describe how genetic counselors can help patients make sense of g...

Personalized Approaches to the Treatment of Prostate Cancer - Kenneth Pienta and James Gulley

Details
Ken Pienta, MD, discusses the role of prostate-specific membrane antigen (PSMA) in facilitating personalized medicine as an imaging agent and selection tool for assigning patients to targeted therapy. He mentions the myriad of trials on PSMA radio-ligand therapeutics that have validated its effect in patients for metastatic prostate cancer. James Gulley, MD, Ph.D., FACS, gives an overview of genom...

Implementation of Germline Testing for Prostate Cancer - Veda Giri

Details
Charles Ryan, MD, and Veda Giri, MD discuss consensus building for germline genetic testing in prostate cancer, a relevant topic given the recent FDA approval of two PARP inhibitors. Dr. Giri reflects on results from the Philadelphia Prostate Cancer Consensus Conference held in October 2019, which sought to address some of the challenges that have arisen as testing has increased and to develop a f...

Clinical Understanding of PARP Inhibitors in Prostate Cancer - Elena Castro, Wassim Abida, and Karen Knudsen

Details
Elena Castro, Wassim Abida, and Karen Knudsen discuss multiple topics regarding the use of PARP inhibitors in prostate cancer treatments. The three debate PARP response data, the functions of PARP inhibitors, the importance of androgen deprivation in the use of PARP inhibitors, and genomic testing in prostate cancer. Biographies: Karen Knudsen, Ph.D., Director, National Cancer Institute (NCI), Sid...

Novel Radiopharmaceuticals In Development For Treatment in Advanced Prostate Cancer - Michael Morris

Details
Michael Morris joins Alicia Morgans to discuss the new agents in development in the field of radiopharmaceuticals in advanced prostate cancer. Historically, much of the research has revolved around bone-targeted radiopharmaceuticals such as radium-223, however, Dr. Morris reviews the development of tumor-directed radiopharmaceuticals that are currently coming into clinical trials. The new therapie...
email news signup